ATE236194T1 - Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe - Google Patents

Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe

Info

Publication number: ATE236194T1
Authority: AT; Austria
Prior art keywords: group; type; anhydro; streptococcus; terminal
Prior art date: 1995-06-07

Application number

AT96918253T

Other languages

English (en)

Inventor

Francis Michon

Dong Catherine

Y Tai Joseph

Original Assignee

North American Vaccine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-06

Publication date

2003-04-15

1996-06-06 Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc

2003-04-15 Application granted granted Critical

2003-04-15 Publication of ATE236194T1 publication Critical patent/ATE236194T1/de

Links

150000004676 glycans Polymers 0.000 title abstract 3
150000004804 polysaccharides Polymers 0.000 title abstract 2
LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical group OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 title 1
108010060123 Conjugate Vaccines Proteins 0.000 title 1
241000193990 Streptococcus sp. 'group B' Species 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
229940031670 conjugate vaccine Drugs 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
230000001268 conjugating effect Effects 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Polymers & Plastics (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Surgical Instruments (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT96918253T 1995-06-07 1996-06-06 Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe ATE236194T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/481,883 US6284884B1 (en)	1995-06-07	1995-06-07	Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
PCT/US1996/009294 WO1996040795A1 (en)	1995-06-07	1996-06-06	Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof

Publications (1)

Publication Number	Publication Date
ATE236194T1 true ATE236194T1 (de)	2003-04-15

Family

ID=23913768

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96918253T ATE236194T1 (de)	1995-06-07	1996-06-06	Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe

Country Status (15)

Country	Link
US (3)	US6284884B1 (de)
EP (1)	EP0830380B1 (de)
JP (1)	JP4001625B2 (de)
KR (1)	KR100431236B1 (de)
AT (1)	ATE236194T1 (de)
AU (1)	AU706479B2 (de)
CA (1)	CA2223080C (de)
DE (1)	DE69627149T2 (de)
ES (1)	ES2200067T3 (de)
HU (1)	HUP9900919A3 (de)
IL (3)	IL136125A (de)
NO (1)	NO975546L (de)
PL (1)	PL187822B1 (de)
WO (1)	WO1996040795A1 (de)
ZA (1)	ZA964822B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2420247A1 (en) *	2000-08-22	2002-02-28	National Research Council Of Canada	Synthesis of complex carbohydrates
CA2881568C (en)	2000-10-27	2019-09-24	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from streptococcus groups a & b
WO2004011027A1 (en) *	2002-07-30	2004-02-05	Baxter International Inc.	Chimeric multivalent polysaccharide conjugate vaccines
US20070053924A1 (en) *	2002-08-26	2007-03-08	Herve Tettelin	Conserved and specific streptococcal genomes
ES2504166T3 (es) *	2002-09-13	2014-10-08	Novartis Vaccines And Diagnostics, Inc.	Vacuna de estreptococo del grupo B
EP1638601B1 (de) *	2003-06-23	2008-11-19	Baxter International Inc.	Trägerproteine für impfstoffe
ES2505695T3 (es)	2003-07-31	2014-10-10	Novartis Vaccines And Diagnostics, Inc.	Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) *	2003-09-15	2015-02-03	Novartis Vaccines And Diagnostics, Srl	Immunogenic compositions for Streptococcus agalactiae
JP2008508320A (ja)	2004-07-29	2008-03-21	カイロンコーポレイション	Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
US7838010B2 (en) *	2004-10-08	2010-11-23	Novartis Vaccines And Diagnostics S.R.L.	Immunogenic and therapeutic compositions for Streptococcus pyogenes
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
CA2620416A1 (en) *	2005-08-24	2007-03-01	Novartis Vaccines And Diagnostics S.R.L.	Zwitterionization of capsular saccharides
PT2054431E (pt) *	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
CA2668018A1 (en) *	2006-10-30	2008-09-12	Novartis Ag	Immunogenic and therapeutic compositions for streptococcus pyogenes
ES2528648T3 (es) *	2007-09-11	2015-02-11	University Of Guelph	Inmunógenos polisacáridos de la Clostridium Difficile
KR101621837B1 (ko)	2007-09-12	2016-05-17	노파르티스 아게	Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2537857B1 (de)	2007-12-21	2017-01-18	GlaxoSmithKline Biologicals SA	Mutante Formen von Streptolysin O
JP5841044B2 (ja) *	2009-03-23	2016-01-06	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	複合糖質ワクチン
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
EP2729178A1 (de)	2011-07-08	2014-05-14	Novartis AG	Tyrosinverbindungsverfahren
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
RU2636350C2 (ru)	2011-11-07	2017-11-22	Новартис Аг	МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
GB201121301D0 (en)	2011-12-12	2012-01-25	Novartis Ag	Method
RU2015106791A (ru)	2012-10-03	2016-11-20	Глэксосмитиклайн Байолоджикалз Са	Иммуногенные композиции
WO2014158963A1 (en) *	2013-03-12	2014-10-02	Wellstat Vaccines, Llc	Antibodies targeted to fungal cell wall polysaccharides
AU2014286990A1 (en)	2013-07-11	2016-02-11	Novartis Ag	Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
BE1024634B1 (fr)	2016-04-05	2018-05-14	Gsk Vaccines S.R.L.	Compositions immunogenes
MX2022015860A (es)	2020-06-12	2023-01-24	Glaxosmithkline Biologicals Sa	Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas.
WO2023111826A1 (en)	2021-12-14	2023-06-22	Glaxosmithkline Biologicals Sa	Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2025172892A1 (en)	2024-02-16	2025-08-21	Glaxosmithkline Biologicals Sa	Modified proteins and methods

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3352773A (en)	1964-09-16	1967-11-14	Gillette Res Inst Inc	Method of degrading polysaccharides using light radiation and a watersoluble metal or nitrogen base salt of nitrous or hyponitric acid
US3922260A (en)	1973-08-24	1975-11-25	Quintin P Peniston	Process for depolymerization of chitosan
US4207414A (en)	1978-08-16	1980-06-10	President And Fellows Of Harvard College	Polysaccharide antigens
US4324887A (en) *	1978-08-16	1982-04-13	President And Fellows Of Harvard College	Type II group B Streptococci polysaccharide
US4500519A (en) *	1978-11-06	1985-02-19	Choay S.A.	Mucopolysaccharides having biological properties, preparation and method of use
US4439422A (en)	1980-01-02	1984-03-27	Research Corporation	Group B Streptococcus antigens and vaccines
US4413057A (en)	1980-04-14	1983-11-01	Merck & Co., Inc.	Group B streptococcal capsular polysaccharides
IE51174B1 (en)	1980-04-14	1986-10-29	Merck & Co Inc	Group b streptococcal capsular polysaccharides
US4438261A (en)	1980-05-19	1984-03-20	Riker Laboratories, Inc.	Anticoagulant substance
US4367221A (en)	1980-06-09	1983-01-04	President And Fellows Of Harvard College	Immunization against Group B streptococci
US4356263A (en)	1980-06-09	1982-10-26	President And Fellows Of Harvard College	Method of making a polysaccharide vaccine
US4367222A (en)	1980-06-09	1983-01-04	President And Fellows Of Harvard College	Immune globulin specific to Group B streptococci
US4367223A (en)	1980-06-09	1983-01-04	President And Fellows Of Harvard College	Vaccine against Group B streptococci
US4284537A (en)	1980-07-03	1981-08-18	The United States Of America As Represented By The Department Of Health And Human Services	Conjugate of streptococcal M protein peptide vaccine
US4425330A (en)	1981-05-20	1984-01-10	Cornell Research Foundation, Inc.	Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) *	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
US4902506A (en)	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US4619828A (en)	1982-07-06	1986-10-28	Connaught Laboratories, Inc.	Polysaccharide exotoxoid conjugate vaccines
US4757134A (en)	1982-12-02	1988-07-12	The Rockefeller University	IgA binding protein
ATE70308T1 (de)	1984-09-12	1991-12-15	Chiron Corp	Hybridpartikel-immunogene.
FR2581877B1 (fr)	1985-05-14	1987-12-18	Louvain Universite Catholique	Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
IT1187753B (it)	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US5302386A (en)	1986-04-16	1994-04-12	Brigham And Women's Hospital, Inc.	Bacterial antigens, antibodies, vaccines and methods of manufacture
JP2754000B2 (ja)	1986-04-16	1998-05-20	ザブリガムアンドウィメンズホスピタル，インコーポレイテッド	細菌抗原、抗体、ワクチン及びその製造方法
NZ225372A (en)	1987-07-17	1991-04-26	Xoma Corp	Immunotoxin composition comprising purified ricin-a-chain species
JP2871822B2 (ja)	1989-08-29	1999-03-17	玉造株式会社	末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
IL95578A (en)	1989-09-15	1998-08-16	Gen Hospital Corp	Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
JPH05502157A (ja)	1989-09-18	1993-04-22	ブリガムアンドウィメンズホスピタル	グループｂ連鎖球菌３型莢膜オリゴ糖の酵素学的産生及び回収
HU9201966D0 (en)	1989-12-14	1992-10-28	Ca Nat Research Council	An improved vaccine of meningococcus-polysaccharide conjunction
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
JPH06506114A (ja)	1991-03-29	1994-07-14	ファウルマン，　エルビン	新規な遺伝子及びＩｇＡ結合蛋白質の製造方法
FR2682388B1 (fr)	1991-10-10	1995-06-09	Pasteur Merieux Serums Vacc	Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5352588A (en)	1991-12-24	1994-10-04	Rockefeller University	Streptococcal immunoglobulin a binding protein encoded by emmL2.2
WO1993015217A1 (en) *	1992-02-04	1993-08-05	Quidel Corporation	Simplified extraction method for bacterial antigens using dried reagents
ZA937034B (en)	1992-09-24	1995-06-23	Brigham & Womens Hospital	Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107458A0 (en)	1992-11-02	1994-02-27	Gen Hospital Corp	Conjugate vaccine against group b streptococcus
US5439808A (en) *	1993-07-23	1995-08-08	North American Vaccine, Inc.	Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5595740A (en) *	1994-05-16	1997-01-21	University Of Florida	Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
WO2000038265A1 (en)	1998-12-22	2000-06-29	Mitsubishi Denki Kabushiki Kaisha	Electrolytic solution for celles and cells made by using the same

1995
- 1995-06-07 US US08/481,883 patent/US6284884B1/en not_active Expired - Fee Related
1996
- 1996-06-06 JP JP50164897A patent/JP4001625B2/ja not_active Expired - Fee Related
- 1996-06-06 CA CA002223080A patent/CA2223080C/en not_active Expired - Fee Related
- 1996-06-06 DE DE69627149T patent/DE69627149T2/de not_active Expired - Fee Related
- 1996-06-06 ES ES96918253T patent/ES2200067T3/es not_active Expired - Lifetime
- 1996-06-06 HU HU9900919A patent/HUP9900919A3/hu unknown
- 1996-06-06 KR KR1019970709189A patent/KR100431236B1/ko not_active Expired - Fee Related
- 1996-06-06 AT AT96918253T patent/ATE236194T1/de not_active IP Right Cessation
- 1996-06-06 PL PL96323822A patent/PL187822B1/pl not_active IP Right Cessation
- 1996-06-06 AU AU60953/96A patent/AU706479B2/en not_active Ceased
- 1996-06-06 WO PCT/US1996/009294 patent/WO1996040795A1/en not_active Ceased
- 1996-06-06 EP EP96918253A patent/EP0830380B1/de not_active Expired - Lifetime
- 1996-06-07 ZA ZA964822A patent/ZA964822B/xx unknown
- 1996-06-07 IL IL136125A patent/IL136125A/en not_active IP Right Cessation
- 1996-06-07 IL IL11860396A patent/IL118603A/xx not_active IP Right Cessation
1997
- 1997-12-02 NO NO975546A patent/NO975546L/no unknown
1998
- 1998-02-18 US US09/025,225 patent/US6372222B1/en not_active Expired - Fee Related
2000
- 2000-05-14 IL IL13612500A patent/IL136125A0/xx active IP Right Grant
2001
- 2001-05-18 US US09/861,131 patent/US6602508B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69627149T2 (de)	2003-12-04
IL118603A (en)	2000-12-06
KR19990022747A (ko)	1999-03-25
US6284884B1 (en)	2001-09-04
US6602508B2 (en)	2003-08-05
EP0830380A1 (de)	1998-03-25
WO1996040795A1 (en)	1996-12-19
CA2223080C (en)	2007-03-20
ZA964822B (en)	1997-01-07
PL187822B1 (pl)	2004-10-29
EP0830380B1 (de)	2003-04-02
ES2200067T3 (es)	2004-03-01
HUP9900919A2 (hu)	1999-06-28
DE69627149D1 (de)	2003-05-08
IL136125A0 (en)	2001-05-20
CA2223080A1 (en)	1996-12-19
IL136125A (en)	2006-08-01
IL118603A0 (en)	1996-10-16
NO975546L (no)	1998-02-06
JP4001625B2 (ja)	2007-10-31
US6372222B1 (en)	2002-04-16
AU6095396A (en)	1996-12-30
NO975546D0 (no)	1997-12-02
HUP9900919A3 (en)	2000-04-28
AU706479B2 (en)	1999-06-17
JPH11507964A (ja)	1999-07-13
PL323822A1 (en)	1998-04-27
US20020031526A1 (en)	2002-03-14
KR100431236B1 (ko)	2004-09-16

Legal Events

Date

Code

Title

Description

2004-08-15

UEP

Publication of translation of european patent specification

Ref document number: 0830380

Country of ref document: EP

2011-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE236194T1 (de)	2003-04-15	Antigene polysaccharidfragmente mit einer terminalen 2,5-anhydro-d-mannosegruppevon gruppe b-streptococcus, typ ii und typ iii, und daraus hergestellte konjugatimpfstoffe
ATE198051T1 (de)	2000-12-15	Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
JP2002539272A5 (de)	2010-11-25
DE68918867D1 (de)	1994-11-17	Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
BR0009163A (pt)	2001-12-26	Vacina
TR199801722T2 (xx)	1998-12-21	Peptit imm�nojenler.
NO20004161L (no)	2000-10-19	Gruppe B streptokoccus antigener
IL128014A (en)	2003-11-23	Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
ATE442439T1 (de)	2009-09-15	Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE146081T1 (de)	1996-12-15	Konjugatimpfstoff für gruppe b-streptococcus
ES2131066T3 (es)	1999-07-16	Vacuna de conjugacion de oligosacarido con adhesina para hi(haemophilus influenzae).
ATE302016T1 (de)	2005-09-15	Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
ATE197645T1 (de)	2000-12-15	Immunoenzymatisches konjugat, herstellungsverfahren dafür und verwendungen
PT774119E (pt)	2004-07-30	Moleculas de suporte oligomericas com grupos marcadores e haptenos incorporados de modo selectivo
Lempert et al.	1988	Isolation of type-nonspecific protein antigens of group B Streptococcus.